I'm just a sideline observer here, but a circa $1M package for the CEO of a biotech company that does not have anything on the market, a declining shareprice, and missed (or delayed) milestones seems a bit excessive IMO.
For example, other CEOs of 'high profile' Australian Biotechs receive far less remuneration for argueably greater performance:
Acrux - Richard Treagus $570,888
Alchemia - Peter Smith $526,470
Starpharma - Jackie Fairley $ 437,841
Biota - Peter Cook $654,571
Healthlinx - Nick Gatsios $329,484
I'm just a sideline observer here, but a circa $1M package for...
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.28 |
Change
-0.250(1.85%) |
Mkt cap ! $664.8M | |||
| Open | High | Low | Value | Volume |
| $13.55 | $13.62 | $13.25 | $1.157M | 86.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 227 | $13.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.42 | 228 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| CUV (ASX) Chart |